Dr. Michael J. Birrer, M.D. PH.D.
Hematology & Oncology (Hematology & Oncology Physician)
At a glance
- Years since graduation
- 44
- In the NPI registry since
- 2007
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
AL license L4584DP · MD license D0032598
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Arkansas Medical Sciences Little Rock, AR
Medical groups
- University of Arkansas for Medical Sciences (1,175 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 5 companies reported 20 payments worth $13,820 in total to this clinician.
| GlaxoSmithKline, LLC. | $9,283 |
|---|---|
| Aadi Bioscience, Inc. | $3,867 |
| Eisai Inc. | $414 |
| AstraZeneca Pharmaceuticals LP | $203 |
| Merck Sharp & Dohme LLC | $53.04 |
| Consulting Fee | $13,069 |
|---|---|
| Food and Beverage | $751 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. Aug 19, 2025 | Consulting Fee | $2,800 |
| GlaxoSmithKline, LLC. Nov 18, 2025 | Consulting Fee | $2,400 |
| Aadi Bioscience, Inc. Sep 2, 2025 | Consulting Fee Fyarro · Cancer | $2,000 |
| GlaxoSmithKline, LLC. Nov 21, 2025 | Consulting Fee | $2,000 |
| Aadi Bioscience, Inc. Oct 31, 2025 | Consulting Fee Fyarro · Cancer | $1,867 |
| GlaxoSmithKline, LLC. Sep 2, 2025 | Consulting Fee ZEJULA · ONCOLOGY | $1,600 |
| GlaxoSmithKline, LLC. Nov 11, 2025 | Consulting Fee | $400 |
| GlaxoSmithKline, LLC. Nov 18, 2025 | Consulting Fee | $2.40 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $121,613 in research payments for these studies, mostly to the institutions running them.
- TAK-280-1501
Takeda Pharmaceuticals U.S.A., Inc. - Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
Aadi Bioscience, Inc. · Recruiting · NCT05997017 - A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
Exelixis Inc. - (VELA) Study of BLU-222 in Advanced Solid Tumors
Sanofi US Services Inc. · Terminated · NCT05252416
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.